Dactinomycin is an intravenously administered, antineoplastic antibiotic that is used in the treatment of solid tumors in children and choriocarcinoma in adult women. In high doses, dactinomycin can cause severe liver injury including sinusoidal obstruction syndrome.
Dactinomycin is a chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine–cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)
Dactinomycin is an Actinomycin. The mechanism of action of dactinomycin is as a Nucleic Acid Synthesis Inhibitor, and Protein Synthesis Inhibitor. A compound composed of two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Daptomycin is a cyclic lipopeptide antibiotic used to treat complicated skin and skin structure infections by susceptible Gram-positive bacteria and bacteremia due to Staphylococcus aureus. Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey.[rx] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.[rx]
Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[rx]
Mechanism of Action
Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis.
The capacity of actinomycins to bind with double-helical DNA is responsible for their biological activity and cytotoxicity. X-ray studies of a crystalline complex between dactinomycin and deoxyguanosine permitted formulation of a model that appears to explain the binding of the drug to DNA. The planar phenoxazone ring intercalates between adjacent guanine–cytosine base pairs of DNA, while the polypeptide chains extend along the minor groove of the helix. The summation of these interactions provides great stability to the dactinomycin-DNA complex, and as a result of the binding of dactinomycin, the transcription of DNA by RNA polymerase is blocked. The DNA-dependent RNA polymerases are much more sensitive to the effects of dactinomycin than are the DNA polymerases. In addition, dactinomycin causes single-strand breaks in DNA, possibly through a free-radical intermediate or as a result of the action of topoisomerase II
Dactinomycin is an antineoplastic antibiotic. The drug has bacteriostatic activity, particularly against gram-positive organisms, but its cytotoxicity precludes its use as an anti-infective agent. Although the exact mechanism(s) of action has not been fully elucidated, the drug appears to inhibit DNA-dependent RNA synthesis by forming a complex with DNA by intercalating with guanine residues and impairing the template activity of DNA. Protein and DNA synthesis are also inhibited but less extensively and at higher concentrations of dactinomycin than are needed to inhibit RNA synthesis. Dactinomycin is immunosuppressive and also possesses some hypocalcemic activity similar to plicamycin.
Generally, the actinomycins exert an inhibitory effect on gram-positive and gram-negative bacteria and on some fungi. However, the toxic properties of the actinomycins (including dactinomycin) in relation to antibacterial activity are such as to preclude their use as antibiotics in the treatment of infectious diseases. Because the actinomycins are cytotoxic, they have an antineoplastic effect which has been demonstrated in experimental animals with various types of tumor implant. This cytotoxic action is the basis for their use in the treatment of certain types of cancer. Dactinomycin is believed to produce its cytotoxic effects by binding DNA and inhibiting RNA synthesis.
Indications
- Antineoplastic; Anti-Bacterial Agents; Nucleic Acid Synthesis Inhibitors; Protein Synthesis Inhibitors
- For the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma, and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen.
- Daptomycin is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in patients one year of age and older. It is also indicated for the treatment of Staphylococcus aureus bloodstream infections (bacteremia) in patients one year of age and older, including in adult patients with right-sided infective endocarditis.[rx]
- Dactinomycin is an intravenously administered, antineoplastic antibiotic that is used in the treatment of solid tumors in children and choriocarcinoma in adult women.
- Dactinomycin, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer.
- Dactinomycin is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia.
- Dactinomycin, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.
- Complicated Skin and Skin Structure Infection
- Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Use in Cancer
Dactinomycin is approved to be used alone or with other drugs to treat:
- Ewing sarcoma in adults and children.
- Gestational trophoblastic disease in adults and children.
- Rhabdomyosarcoma in adults and children.
- Solid tumors that are locally recurrent. It is used as palliative and/or adjuvant therapy in adults.
- Testicular cancer. It is used in adults and children whose nonseminomas have metastasized (spread to other parts of the body).
- Wilms tumor in adults and children.
Dactinomycin is also being studied in the treatment of other types of cancer.
Contraindications
- Serious rash.
- New primary malignancy.
- Anemia, bone marrow suppression, geriatric, neutropenia, thrombocytopenia.
- Herpes infection, infection.
- Extravasation.
- Children, hepatotoxicity, infants, sinusoidal obstruction syndrome (SOS), veno-occlusive disease (VOD)
- Radiation therapy.
- shingles
- a bad infection
- low blood counts due to bone marrow failure
- anemia
- decreased blood platelets
- low levels of white blood cells
- low levels of a type of white blood cell called neutrophils
- a blood clot in a vein of the liver
- liver problems
- ascites
- abnormal liver function tests
- pregnancy
- a patient who is producing milk and breastfeeding
- infection caused by the varicella zoster virus
- exposure to the chickenpox
Dosage
Strengths: 0.5 mg
Wilms’ Tumor
- As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks
- For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen
Rhabdomyosarcoma
- As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks
- For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen
Ewing’s Sarcoma
- As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks
- For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen
Testicular Cancer
- As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks
- For the treatment of metastatic nonseminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen
Trophoblastic Disease
- As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days
- As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks
- For the treatment of post-menarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen
Solid Tumors
- In combination with melphalan for lower extremity or pelvis: 50 mcg/kg IV over 10 to 15 minutes once
- In combination with melphalan for upper extremity: 35 mcg/kg IV once
- For the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion
Usual Pediatric Dose
Wilms’ Tumor
- As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks
- For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen
Rhabdomyosarcoma
- As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks
- For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen
Ewing’s Sarcoma
- As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks
- For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen
Testicular Cancer
- As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks
- For the treatment of metastatic nonseminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen
Trophoblastic Disease
- As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days
- As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks
- For the treatment of post-menarchal pediatric patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen
Dose Adjustments
Calculate the dose for obese or edematous patients based on ideal body weight.
Administration advice:
- Administer the diluted reconstituted product IV over 10 to 15 minutes.
- Do not use in-line filters with a cellulose ester membrane.
Side Effects
The Most Common
- Common adverse drug reaction includes bone marrow suppression, fatigue, hair loss, mouth ulcer, loss of appetite and diarrhea. Actinomycin is a vesicant, if extravasation occurs.
- vomiting
- stomach pain
- diarrhea
- hair loss
- hives
- rash
- difficulty breathing or swallowing
- nausea
- extreme tiredness
- unusual bleeding or bruising
- sores in the mouth and throat
- lack of energy
- loss of appetite
- pain in the upper right part of the stomach
- yellowing of the skin or eyes
- fever, sore throat, ongoing cough and congestion, or other signs of infection
- unusual bleeding or bruising
- black and tarry stools
- red blood in stools
More common
- Black, tarry stools
- blood in the urine or stools
- chills
- cough
- diarrhea (continuing)
- difficulty with swallowing
- fever
- heartburn
- hoarseness
- lower back or side pain
- painful or difficult urination
- pinpoint red spots on the skin
- sores in the mouth and on the lips
- stomach pain (continuing)
- unusual bleeding or bruising
- unusual tiredness or weakness
- swelling or tenderness in your stomach (upper right side), rapid weight gain;
- swelling in your arms or legs;
- dark urine, jaundice (yellowing of the skin or eyes);
- redness of your skin or the inside of your mouth and throat (if you are also receiving radiation treatment);
- sores or white patches in or around your mouth, trouble swallowing or talking, dry mouth, bad breath, altered sense of taste;
- blisters, ulcers, or other skin changes where an injection was given; or
- low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath.
Rare
- Blistering, peeling, or loosening of the skin
- body aches or pain
- chapped, red, or swollen lips
- confusion
- congestion
- cough
- difficulty with breathing
- difficulty with moving
- difficulty with swallowing
- dryness or soreness of the throat
- flushing or redness of the skin
- irregular heartbeat
- joint pain or swelling
- muscle ache, pains, or stiffness
- muscle cramps in the hands, arms, feet, legs, or face
- numbness and tingling around the mouth, fingertips, or feet
- pain at the injection site
- runny nose
- scaling, redness, burning, pain, or other signs of inflammation of the lips
- seizures
- slow growth
- stomach cramps
- swelling of the feet or lower legs
- tender, swollen glands in the neck
- tremor
- unusually warm skin
- voice changes
- yellow eyes or skin
Drug Interaction
DRUG | INTERACTION |
---|---|
Abacavir | Daptomycin may decrease the excretion rate of Abacavir which could result in a higher serum level. |
Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Daptomycin. |
Abrocitinib | The serum concentration of Daptomycin can be increased when it is combined with Abrocitinib. |
Aceclofenac | Aceclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Acemetacin | Acemetacin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Acenocoumarol | The risk or severity of bleeding can be increased when Daptomycin is combined with Acenocoumarol. |
Acetaminophen | Daptomycin may decrease the excretion rate of Acetaminophen which could result in a higher serum level. |
Acetazolamide | Acetazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Acetylsalicylic acid | Acetylsalicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Acipimox | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Acipimox. |
Aclidinium | Daptomycin may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
Acrivastine | Daptomycin may decrease the excretion rate of Acrivastine which could result in a higher serum level. |
Acyclovir | Acyclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Adefovir dipivoxil | Adefovir dipivoxil may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Afatinib | The serum concentration of Daptomycin can be increased when it is combined with Afatinib. |
Albutrepenonacog | Daptomycin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. |
Alclofenac | Alclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Aldesleukin | Aldesleukin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Alendronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid. |
Allopurinol | Daptomycin may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
Almasilate | Daptomycin may decrease the excretion rate of Almasilate which could result in a higher serum level. |
Almotriptan | Daptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level. |
Alogliptin | Daptomycin may decrease the excretion rate of Alogliptin which could result in a higher serum level. |
Alprazolam | Daptomycin may decrease the excretion rate of Alprazolam which could result in a higher serum level. |
Amantadine | Daptomycin may decrease the excretion rate of Amantadine which could result in a higher serum level. |
Ambrisentan | The serum concentration of Ambrisentan can be increased when it is combined with Daptomycin. |
Amikacin | Daptomycin may decrease the excretion rate of Amikacin which could result in a higher serum level. |
Amiloride | Amiloride may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Aminophenazone | Aminophenazone may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Amiodarone | The serum concentration of Daptomycin can be increased when it is combined with Amiodarone. |
Amitriptyline | Daptomycin may decrease the excretion rate of Amitriptyline which could result in a higher serum level. |
Ammonium chloride | Daptomycin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. |
Amoxicillin | Daptomycin may decrease the excretion rate of Amoxicillin which could result in a higher serum level. |
Amphetamine | Daptomycin may decrease the excretion rate of Amphetamine which could result in a higher serum level. |
Amphotericin B | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Amphotericin B. |
Ampicillin | Daptomycin may decrease the excretion rate of Ampicillin which could result in a higher serum level. |
Amrinone | Daptomycin may decrease the excretion rate of Amrinone which could result in a higher serum level. |
Ancestim | Daptomycin may decrease the excretion rate of Ancestim which could result in a higher serum level. |
Antihemophilic | Daptomycin may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. |
Antipyrine | Antipyrine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Antithrombin | Daptomycin may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. |
Antrafenine | Antrafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Apalutamide | The serum concentration of Daptomycin can be decreased when it is combined with Apalutamide. |
Apixaban | The serum concentration of Apixaban can be increased when it is combined with Daptomycin. |
Apremilast | Daptomycin may decrease the excretion rate of Apremilast which could result in a higher serum level. |
Arformoterol | Daptomycin may decrease the excretion rate of Arformoterol which could result in a higher serum level. |
Arsenic trioxide | The serum concentration of Daptomycin can be increased when it is combined with Arsenic trioxide. |
Articaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Articaine. |
Asciminib | The serum concentration of Daptomycin can be increased when it is combined with Asciminib. |
Asunaprevir | The serum concentration of Daptomycin can be increased when it is combined with Asunaprevir. |
Atazanavir | Atazanavir may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Atomoxetine | Daptomycin may decrease the excretion rate of Atomoxetine which could result in a higher serum level. |
Atorvastatin | The risk or severity of myopathy can be increased when Atorvastatin is combined with Daptomycin. |
Auranofin | Daptomycin may decrease the excretion rate of Auranofin which could result in a higher serum level. |
Aurothioglucose | Daptomycin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. |
Avanafil | The serum concentration of Avanafil can be increased when it is combined with Daptomycin. |
Avatrombopag | The serum concentration of Avatrombopag can be increased when it is combined with Daptomycin. |
Axitinib | The serum concentration of Axitinib can be increased when it is combined with Daptomycin. |
Azacitidine | Daptomycin may decrease the excretion rate of Azacitidine which could result in a higher serum level. |
Azathioprine | Daptomycin may decrease the excretion rate of Azathioprine which could result in a higher serum level. |
Azelaic acid | Daptomycin may decrease the excretion rate of Azelaic acid which could result in a higher serum level. |
Aztreonam | Daptomycin may decrease the excretion rate of Aztreonam which could result in a higher serum level. |
Bacitracin | Bacitracin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Baclofen | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Baclofen. |
Balsalazide | Balsalazide may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Baricitinib | Daptomycin may decrease the excretion rate of Baricitinib which could result in a higher serum level. |
BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daptomycin. |
Belantamab | The serum concentration of Belantamab mafodotin can be increased when it is combined with Daptomycin. |
Belinostat | The serum concentration of Belinostat can be increased when it is combined with Daptomycin. |
Belumosudil | The serum concentration of Daptomycin can be increased when it is combined with Belumosudil. |
Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Daptomycin. |
Bendroflumet | Bendroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Benorilate | Benorilate may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Benoxaprofen | Benoxaprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Benserazide | Daptomycin may decrease the excretion rate of Benserazide which could result in a higher serum level. |
Benzatropine | Daptomycin may decrease the excretion rate of Benzatropine which could result in a higher serum level. |
Benznidazole | Daptomycin may decrease the excretion rate of Benznidazole which could result in a higher serum level. |
Benzocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Benzocaine. |
Benzthiazide | Benzthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Benzydamine | Benzydamine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Benzyl alcohol. |
Bepotastine | Daptomycin may decrease the excretion rate of Bepotastine which could result in a higher serum level. |
Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Daptomycin. |
Betamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Betamethasone. |
Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Daptomycin. |
Bezafibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Bezafibrate. |
Bicisate | Daptomycin may decrease the excretion rate of Bicisate which could result in a higher serum level. |
Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Daptomycin. |
Bismuth subgallate | Daptomycin may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. |
Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Daptomycin. |
Bisoxatin | Daptomycin may decrease the excretion rate of Bisoxatin which could result in a higher serum level. |
Bleomycin | Daptomycin may decrease the excretion rate of Bleomycin which could result in a higher serum level. |
Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Daptomycin. |
Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Daptomycin. |
Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Daptomycin. |
Brivaracetam | Daptomycin may decrease the excretion rate of Brivaracetam which could result in a higher serum level. |
Bromazepam | Daptomycin may decrease the excretion rate of Bromazepam which could result in a higher serum level. |
Bromotheophylline | Bromotheophylline may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Budesonide | Daptomycin may decrease the excretion rate of Budesonide which could result in a higher serum level. |
Bumadizone | Bumadizone may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Bumetanide | Bumetanide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Bupivacaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Bupivacaine. |
Bupropion | Daptomycin may decrease the excretion rate of Bupropion which could result in a higher serum level. |
Buspirone | Daptomycin may decrease the excretion rate of Buspirone which could result in a higher serum level. |
Butabarbital | Daptomycin may decrease the excretion rate of Butabarbital which could result in a higher serum level. |
Butacaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Butacaine. |
Butamben | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Butamben. |
Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Daptomycin. |
Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Daptomycin. |
Canagliflozin | The serum concentration of Daptomycin can be increased when it is combined with Canagliflozin. |
Canrenoic acid | Canrenoic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Capecitabine | Daptomycin may decrease the excretion rate of Capecitabine which could result in a higher serum level. |
Capmatinib | The serum concentration of Daptomycin can be increased when it is combined with Capmatinib. |
Capreomycin | Daptomycin may decrease the excretion rate of Capreomycin which could result in a higher serum level. |
Capsaicin | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Capsaicin. |
Captopril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Captopril. |
Carbamazepine | Daptomycin may decrease the excretion rate of Carbamazepine which could result in a higher serum level. |
Carbidopa | Daptomycin may decrease the excretion rate of Carbidopa which could result in a higher serum level. |
Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Carbimazole. |
Carboplatin | Carboplatin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Carfilzomib | The serum concentration of Daptomycin can be increased when it is combined with Carfilzomib. |
Carmustine | Daptomycin may decrease the excretion rate of Carmustine which could result in a higher serum level. |
Carprofen | Carprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Carvedilol | The serum concentration of Daptomycin can be increased when it is combined with Carvedilol. |
Cefaclor | Cefaclor may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefadroxil | Cefadroxil may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefalotin | Cefalotin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefamandole | Cefamandole may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefapirin | Cefapirin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefazolin | Cefazolin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefdinir | Daptomycin may decrease the excretion rate of Cefdinir which could result in a higher serum level. |
Cefditoren | Cefditoren may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefepime | Cefepime may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefmenoxime | Cefmenoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefmetazole | Cefmetazole may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefonicid | Cefonicid may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefoperazone | Cefoperazone may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceforanide | Ceforanide may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefotaxime | Cefotaxime may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefotetan | Cefotetan may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefotiam | Cefotiam may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefoxitin | Cefoxitin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefpiramide | Cefpiramide may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefpirome | Cefpirome may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefpodoxime | Cefpodoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefprozil | Cefprozil may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefradine | Cefradine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceftaroline fosamil | Ceftaroline fosamil may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceftazidime | Ceftazidime may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceftibuten | Ceftibuten may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceftizoxime | Ceftizoxime may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceftobiprole | Ceftobiprole may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceftolozane | Daptomycin may decrease the excretion rate of Ceftolozane which could result in a higher serum level. |
Ceftriaxone | Ceftriaxone may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cefuroxime | Cefuroxime may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Celecoxib | Celecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cephalexin | Cephalexin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cephaloglycin | Cephaloglycin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Daptomycin. |
Cerivastatin | The risk or severity of myopathy can be increased when Cerivastatin is combined with Daptomycin. |
Certolizumab pegol | Daptomycin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level. |
Cetirizine | Daptomycin may decrease the excretion rate of Cetirizine which could result in a higher serum level. |
Cevimeline | Daptomycin may decrease the excretion rate of Cevimeline which could result in a higher serum level. |
Chloral hydrate | Daptomycin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level. |
Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Chloroprocaine. |
Chloroquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Chloroquine. |
Chlorothiazide | Chlorothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Chloroxylenol | Daptomycin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. |
Chlorpromazine | Daptomycin may decrease the excretion rate of Chlorpromazine which could result in a higher serum level. |
Chlorpropamide | Daptomycin may decrease the excretion rate of Chlorpropamide which could result in a higher serum level. |
Chlorthalidone | Chlorthalidone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Chlorzoxazone | Daptomycin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level. |
Choline C 11 | Daptomycin may decrease the excretion rate of Choline C 11 which could result in a higher serum level. |
Choline magnesium | Choline magnesium trisalicylate may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Choline salicylate | Daptomycin may decrease the excretion rate of Choline salicylate which could result in a higher serum level. |
Chondroitin sulfate | Daptomycin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. |
Chromic chloride | Daptomycin may decrease the excretion rate of Chromic chloride which could result in a higher serum level. |
Chromic nitrate | Daptomycin may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. |
Chromium | Daptomycin may decrease the excretion rate of Chromium which could result in a higher serum level. |
Chromium gluconate | Daptomycin may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. |
Chromium nicotinate | Daptomycin may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. |
Chromous sulfate | Daptomycin may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. |
Cidofovir | Cidofovir may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Cilostazol | Daptomycin may decrease the excretion rate of Cilostazol which could result in a higher serum level. |
Cimetidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cimetidine. |
Cinchocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Cinchocaine. |
Ciprofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofibrate. |
Ciprofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ciprofloxacin. |
Cisatracurium | Daptomycin may increase the neuromuscular blocking activities of Cisatracurium. |
Cisplatin | Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. |
Cladribine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cladribine. |
Clarithromycin | The serum concentration of Daptomycin can be increased when it is combined with Clarithromycin. |
Clevidipine | Daptomycin may decrease the excretion rate of Clevidipine which could result in a higher serum level. |
Clobazam | The serum concentration of Clobazam can be increased when it is combined with Daptomycin. |
Clofarabine | Daptomycin may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
Clofazimine | The serum concentration of Daptomycin can be increased when it is combined with Clofazimine. |
Clofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Clofibrate. |
Clomifene | The serum concentration of Clomifene can be increased when it is combined with Daptomycin. |
Clomipramine | Daptomycin may decrease the excretion rate of Clomipramine which could result in a higher serum level. |
Clonazepam | Daptomycin may decrease the excretion rate of Clonazepam which could result in a higher serum level. |
Clorazepic acid | Daptomycin may decrease the excretion rate of Clorazepic acid which could result in a higher serum level. |
Clove oil | Daptomycin may decrease the excretion rate of Clove oil which could result in a higher serum level. |
Clozapine | Daptomycin may decrease the excretion rate of Clozapine which could result in a higher serum level. |
Cobicistat | The serum concentration of Daptomycin can be increased when it is combined with Cobicistat. |
Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Daptomycin. |
Cocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Cocaine. |
Colchicine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Colchicine. |
Colistimethate | Colistimethate may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Colistin | Daptomycin may decrease the excretion rate of Colistin which could result in a higher serum level. |
Conivaptan | The serum concentration of Daptomycin can be increased when it is combined with Conivaptan. |
C. estrogens | Daptomycin may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Daptomycin. |
Corifollitropin alfa | Daptomycin may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. |
Crizotinib | The serum concentration of Daptomycin can be increased when it is combined with Crizotinib. |
Curcumin | The serum concentration of Daptomycin can be increased when it is combined with Curcumin. |
Cyanocobalamin | Daptomycin may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level. |
Cyclopenthiazide | Cyclopenthiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Cyclosporine | The serum concentration of Daptomycin can be increased when it is combined with Cyclosporine. |
Cyclothiazide | Cyclothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Cytarabine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine. |
Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be increased when it is combined with Daptomycin. |
Dabrafenib | The serum concentration of Dabrafenib can be increased when it is combined with Daptomycin. |
Dacarbazine | Daptomycin may decrease the excretion rate of Dacarbazine which could result in a higher serum level. |
Daclatasvir | The serum concentration of Daptomycin can be increased when it is combined with Daclatasvir. |
Dacomitinib | The serum concentration of Daptomycin can be increased when it is combined with Dacomitinib. |
Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Daptomycin. |
Dalfampridine | Daptomycin may decrease the excretion rate of Dalfampridine which could result in a higher serum level. |
Dapagliflozin | Dapagliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Darolutamide | The serum concentration of Darolutamide can be increased when it is combined with Daptomycin. |
Darunavir | The serum concentration of Darunavir can be increased when it is combined with Daptomycin. |
Dasabuvir | The serum concentration of Dasabuvir can be increased when it is combined with Daptomycin. |
Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Daptomycin. |
Deferiprone | Daptomycin may decrease the excretion rate of Deferiprone which could result in a higher serum level. |
Delafloxacin | Daptomycin may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
Desipramine | Daptomycin may decrease the excretion rate of Desipramine which could result in a higher serum level. |
Desmopressin | Desmopressin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Desvenlafaxine | Daptomycin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. |
Deutetrabenazine | Daptomycin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. |
Dexamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Dexamethasone. |
Dexibuprofen | Dexibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Dexketoprofen | Dexketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Dexmedetomidine | Daptomycin may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level. |
Dexpanthenol | Daptomycin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. |
Dexrazoxane | Daptomycin may decrease the excretion rate of Dexrazoxane which could result in a higher serum level. |
Dextran | Daptomycin may decrease the excretion rate of Dextran which could result in a higher serum level. |
Diatrizoate | Daptomycin may decrease the excretion rate of Diatrizoate which could result in a higher serum level. |
Diazepam | Daptomycin may decrease the excretion rate of Diazepam which could result in a higher serum level. |
Dichlorobenzyl | Daptomycin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. |
Diclofenac | Diclofenac may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Diclofenamide | Diclofenamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Dicoumarol | The risk or severity of bleeding can be increased when Daptomycin is combined with Dicoumarol. |
Dicyclomine | Daptomycin may decrease the excretion rate of Dicyclomine which could result in a higher serum level. |
Didanosine | Daptomycin may decrease the excretion rate of Didanosine which could result in a higher serum level. |
Dienogest | Daptomycin may decrease the excretion rate of Dienogest which could result in a higher serum level. |
Diflunisal | Diflunisal may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Difluocortolone | Daptomycin may decrease the excretion rate of Difluocortolone which could result in a higher serum level. |
Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Daptomycin. |
Digoxin | Daptomycin may decrease the excretion rate of Digoxin which could result in a higher serum level. |
Dihydrostrep | Dihydrostreptomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Dimercaprol | Daptomycin may decrease the excretion rate of Dimercaprol which could result in a higher serum level. |
Dimethyl sulfoxide | Daptomycin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level. |
Diosmin | The serum concentration of Daptomycin can be increased when it is combined with Diosmin. |
Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Diphenhydramine. |
Disopyramide | Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level. |
Methylephedrine | Daptomycin may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. |
Dobutamine | Daptomycin may decrease the excretion rate of Dobutamine which could result in a higher serum level. |
Docetaxel | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Docetaxel. |
Dolutegravir | The serum concentration of Dolutegravir can be increased when it is combined with Daptomycin. |
Dopamine | Daptomycin may decrease the excretion rate of Dopamine which could result in a higher serum level. |
Doripenem | Daptomycin may decrease the excretion rate of Doripenem which could result in a higher serum level. |
Doxacurium | Daptomycin may decrease the excretion rate of Doxacurium which could result in a higher serum level. |
Doxepin | Daptomycin may decrease the excretion rate of Doxepin which could result in a higher serum level. |
Doxycycline | Daptomycin may decrease the excretion rate of Doxycycline which could result in a higher serum level. |
Dronedarone | The serum concentration of Daptomycin can be increased when it is combined with Dronedarone. |
Drospirenone | Drospirenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Droxidopa | Daptomycin may decrease the excretion rate of Droxidopa which could result in a higher serum level. |
Duloxetine | Daptomycin may decrease the excretion rate of Duloxetine which could result in a higher serum level. |
Duvelisib | The serum concentration of Duvelisib can be increased when it is combined with Daptomycin. |
Dyclonine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Dyclonine. |
Dyphylline | Daptomycin may decrease the excretion rate of Dyphylline which could result in a higher serum level. |
Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Daptomycin. |
Edrophonium | Daptomycin may decrease the excretion rate of Edrophonium which could result in a higher serum level. |
Elagolix | The serum concentration of Daptomycin can be increased when it is combined with Elagolix. |
Elbasvir | The serum concentration of Elbasvir can be increased when it is combined with Daptomycin. |
Eliglustat | The serum concentration of Daptomycin can be increased when it is combined with Eliglustat. |
Enalapril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Enalapril. |
Enalaprilat | Daptomycin may decrease the excretion rate of Enalaprilat which could result in a higher serum level. |
Enasidenib | The serum concentration of Daptomycin can be increased when it is combined with Enasidenib. |
Enfortumab vedotin | The serum concentration of Enfortumab vedotin can be increased when it is combined with Daptomycin. |
Entrectinib | The serum concentration of Daptomycin can be increased when it is combined with Entrectinib. |
Enzalutamide | Daptomycin may decrease the excretion rate of Enzalutamide which could result in a higher serum level. |
Eplerenone | Eplerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Epoprostenol | Daptomycin may decrease the excretion rate of Epoprostenol which could result in a higher serum level. |
Eprosartan | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Eprosartan. |
Erdafitinib | The serum concentration of Daptomycin can be increased when it is combined with Erdafitinib. |
Ertapenem | Daptomycin may decrease the excretion rate of Ertapenem which could result in a higher serum level. |
Ertugliflozin | Ertugliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Erythromycin | The serum concentration of Daptomycin can be increased when it is combined with Erythromycin. |
Estazolam | Daptomycin may decrease the excretion rate of Estazolam which could result in a higher serum level. |
Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Daptomycin. |
Estradiol | Daptomycin may decrease the excretion rate of Estradiol which could result in a higher serum level. |
Estradiol acetate | Daptomycin may decrease the excretion rate of Estradiol acetate which could result in a higher serum level. |
Estradiol cypionate | Daptomycin may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level. |
Estradiol dienanthate | Daptomycin may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. |
Estradiol valerate | Daptomycin may decrease the excretion rate of Estradiol valerate which could result in a higher serum level. |
Estrone sulfate | Daptomycin may decrease the excretion rate of Estrone sulfate which could result in a higher serum level. |
Eszopiclone | Daptomycin may decrease the excretion rate of Eszopiclone which could result in a higher serum level. |
Etacrynic acid | Etacrynic acid may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Etafedrine | Daptomycin may decrease the excretion rate of Etafedrine which could result in a higher serum level. |
Ethambutol | Daptomycin may decrease the excretion rate of Ethambutol which could result in a higher serum level. |
Ethanol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ethanol. |
Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Ethyl chloride. |
Etidocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Etidocaine. |
Etodolac | Etodolac may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Etomidate | Daptomycin may decrease the excretion rate of Etomidate which could result in a higher serum level. |
Etonogestrel | Daptomycin may decrease the excretion rate of Etonogestrel which could result in a higher serum level. |
Etoposide | The serum concentration of Etoposide can be increased when it is combined with Daptomycin. |
Etoricoxib | Etoricoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Eucalyptus oil | Daptomycin may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. |
Everolimus | The serum concentration of Daptomycin can be increased when it is combined with Everolimus. |
Ezogabine | Daptomycin may decrease the excretion rate of Ezogabine which could result in a higher serum level. |
Favipiravir | The serum concentration of Daptomycin can be increased when it is combined with Favipiravir. |
Fedratinib | The serum concentration of Daptomycin can be increased when it is combined with Fedratinib. |
Fenbufen | Fenbufen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Fenofibrate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibrate. |
Fenofibric acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fenofibric acid. |
Fenoldopam | Daptomycin may decrease the excretion rate of Fenoldopam which could result in a higher serum level. |
Fenoprofen | Fenoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Fentanyl | Daptomycin may decrease the excretion rate of Fentanyl which could result in a higher serum level. |
Fesoterodine | Daptomycin may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
Fexofenadine | The serum concentration of Fexofenadine can be increased when it is combined with Daptomycin. |
Finerenone | Finerenone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Flavoxate | Daptomycin may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
Flibanserin | The serum concentration of Daptomycin can be increased when it is combined with Flibanserin. |
Floctafenine | Floctafenine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Florbetaben | Daptomycin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. |
Florbetapir | Daptomycin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. |
Floxuridine | Daptomycin may decrease the excretion rate of Floxuridine which could result in a higher serum level. |
Fluconazole | The serum concentration of Daptomycin can be increased when it is combined with Fluconazole. |
Flucytosine | Daptomycin may decrease the excretion rate of Flucytosine which could result in a higher serum level. |
Fludeoxyglucose | Daptomycin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. |
Fluindione | The risk or severity of bleeding can be increased when Daptomycin is combined with Fluindione. |
Flumazenil | Daptomycin may decrease the excretion rate of Flumazenil which could result in a higher serum level. |
Fluocinolone | Daptomycin may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level. |
Flurazepam | Daptomycin may decrease the excretion rate of Flurazepam which could result in a higher serum level. |
Flurbiprofen | Flurbiprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Flutamide | Daptomycin may decrease the excretion rate of Flutamide which could result in a higher serum level. |
Fluvastatin | The risk or severity of myopathy can be increased when Fluvastatin is combined with Daptomycin. |
Fluvoxamine | Daptomycin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level. |
Folic acid | Daptomycin may decrease the excretion rate of Folic acid which could result in a higher serum level. |
Fomepizole | Daptomycin may decrease the excretion rate of Fomepizole which could result in a higher serum level. |
Fondaparinux | Daptomycin may decrease the excretion rate of Fondaparinux which could result in a higher serum level. |
Formestane | Daptomycin may decrease the excretion rate of Formestane which could result in a higher serum level. |
Foscarnet | Foscarnet may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Fosfomycin | Daptomycin may decrease the excretion rate of Fosfomycin which could result in a higher serum level. |
Fosinopril | Daptomycin may decrease the excretion rate of Fosinopril which could result in a higher serum level. |
Fostemsavir | The serum concentration of Fostemsavir can be increased when it is combined with Daptomycin. |
Framycetin | Framycetin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Furosemide | Furosemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Fusidic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Fusidic acid. |
Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Daptomycin. |
Gabapentin | Daptomycin may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. |
Gadobenic acid | Daptomycin may decrease the excretion rate of Gadobenic acid which could result in a higher serum level. |
Gadodiamide | Daptomycin may decrease the excretion rate of Gadodiamide which could result in a higher serum level. |
Gadofosveset | Daptomycin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. |
Gadopentetic acid | Daptomycin may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level. |
Gadoteric acid | Daptomycin may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. |
Gadoteridol | Daptomycin may decrease the excretion rate of Gadoteridol which could result in a higher serum level. |
Ganciclovir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ganciclovir. |
Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Daptomycin. |
Gemfibrozil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Gemfibrozil. |
Gentamicin | Daptomycin may decrease the excretion rate of Gentamicin which could result in a higher serum level. |
Gilteritinib | The serum concentration of Gilteritinib can be increased when it is combined with Daptomycin. |
Gimeracil | Daptomycin may decrease the excretion rate of Gimeracil which could result in a higher serum level. |
Givosiran | Givosiran may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Glasdegib | The serum concentration of Daptomycin can be increased when it is combined with Glasdegib. |
Glecaprevir | The serum concentration of Daptomycin can be increased when it is combined with Glecaprevir. |
Glipizide | Daptomycin may decrease the excretion rate of Glipizide which could result in a higher serum level. |
Glycerol | Daptomycin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. |
Golodirsen | Daptomycin may decrease the excretion rate of Golodirsen which could result in a higher serum level. |
Goserelin | Goserelin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Grazoprevir | The serum concentration of Grazoprevir can be increased when it is combined with Daptomycin. |
Guanethidine | Daptomycin may decrease the excretion rate of Guanethidine which could result in a higher serum level. |
Guanfacine | Daptomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level. |
Haloperidol | Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level. |
Hydralazine | Daptomycin may decrease the excretion rate of Hydralazine which could result in a higher serum level. |
Hydrochlorothiazide | Hydrochlorothiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Hydroflumethiazide | Hydroflumethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Hydromorphone | Daptomycin may decrease the excretion rate of Hydromorphone which could result in a higher serum level. |
Hydroxocobalamin | Daptomycin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level. |
Hydroxyethyl Starch | Daptomycin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. |
Ibandronate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ibandronate. |
Ibuprofen | Ibuprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ibutilide | Daptomycin may decrease the excretion rate of Ibutilide which could result in a higher serum level. |
Icatibant | Daptomycin may decrease the excretion rate of Icatibant which could result in a higher serum level. |
Icosapent | Icosapent may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Idarucizumab | Daptomycin may decrease the excretion rate of Idarucizumab which could result in a higher serum level. |
Idebenone | Daptomycin may decrease the excretion rate of Idebenone which could result in a higher serum level. |
Idelalisib | The serum concentration of Idelalisib can be increased when it is combined with Daptomycin. |
Ifosfamide | Daptomycin may decrease the excretion rate of Ifosfamide which could result in a higher serum level. |
Iloprost | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Iloprost. |
Imipramine | The serum concentration of Imipramine can be increased when it is combined with Daptomycin. |
Indacaterol | The serum concentration of Indacaterol can be increased when it is combined with Daptomycin. |
Indapamide | Indapamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Indigotindisulfonic | Daptomycin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. |
Indinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Indinavir. |
Indomethacin | Indomethacin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Infliximab | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Daptomycin. |
Inosine pranobex | Daptomycin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. |
Inositol | Daptomycin may decrease the excretion rate of Inositol which could result in a higher serum level. |
Inotersen | Inotersen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Inotuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Daptomycin. |
Iobenguane sulfate | Daptomycin may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. |
Iodixanol | Daptomycin may decrease the excretion rate of Iodixanol which could result in a higher serum level. |
Ioflupane | Daptomycin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. |
Iopromide | Daptomycin may decrease the excretion rate of Iopromide which could result in a higher serum level. |
Iothalamic acid | Daptomycin may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. |
Ioversol | Daptomycin may decrease the excretion rate of Ioversol which could result in a higher serum level. |
Ioxilan | Daptomycin may decrease the excretion rate of Ioxilan which could result in a higher serum level. |
Ipecac | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ipecac. |
Ipilimumab | Daptomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. |
Isavuconazole | The serum concentration of Daptomycin can be increased when it is combined with Isavuconazole. |
Isavuconazonium | The serum concentration of Daptomycin can be increased when it is combined with Isavuconazonium. |
Isoniazid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Isoniazid. |
Isosorbide | Isosorbide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Isosorbide | Daptomycin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level. |
Isosulfan blue | Daptomycin may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. |
Isotretinoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Isotretinoin. |
Isoxicam | Isoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Isradipine | Daptomycin may decrease the excretion rate of Isradipine which could result in a higher serum level. |
Istradefylline | The serum concentration of Daptomycin can be increased when it is combined with Istradefylline. |
Itraconazole | The serum concentration of Daptomycin can be increased when it is combined with Itraconazole. |
Ivacaftor | The serum concentration of Daptomycin can be increased when it is combined with Ivacaftor. |
Ivermectin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ivermectin. |
Ixabepilone | The serum concentration of Daptomycin can be increased when it is combined with Ixabepilone. |
Ixazomib | Daptomycin may decrease the excretion rate of Ixazomib which could result in a higher serum level. |
Kanamycin | Daptomycin may decrease the excretion rate of Kanamycin which could result in a higher serum level. |
Ketamine | Daptomycin may decrease the excretion rate of Ketamine which could result in a higher serum level. |
Ketazolam | Daptomycin may decrease the excretion rate of Ketazolam which could result in a higher serum level. |
Ketoconazole | The serum concentration of Daptomycin can be increased when it is combined with Ketoconazole. |
Ketoprofen | Ketoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ketorolac | Ketorolac may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Labetalol | Daptomycin may decrease the excretion rate of Labetalol which could result in a higher serum level. |
Lamivudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lamivudine. |
Lamotrigine | Daptomycin may decrease the excretion rate of Lamotrigine which could result in a higher serum level. |
Lapatinib | The serum concentration of Daptomycin can be increased when it is combined with Lapatinib. |
Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Daptomycin. |
Lasmiditan | The serum concentration of Daptomycin can be increased when it is combined with Lasmiditan. |
Latamoxef | Latamoxef may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ledipasvir | The serum concentration of Daptomycin can be increased when it is combined with Ledipasvir. |
Lefamulin | The serum concentration of Lefamulin can be increased when it is combined with Daptomycin. |
Leflunomide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Leflunomide. |
Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Daptomycin. |
Lenalidomide | Daptomycin may decrease the excretion rate of Lenalidomide which could result in a higher serum level. |
Lenvatinib | The serum concentration of Lenvatinib can be increased when it is combined with Daptomycin. |
Lercanidipine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Lercanidipine. |
Lesinurad | Daptomycin may decrease the excretion rate of Lesinurad which could result in a higher serum level. |
Letrozole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Letrozole. |
Leuprolide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin. |
Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Levobupivacaine. |
Levocarnitine | Daptomycin may decrease the excretion rate of Levocarnitine which could result in a higher serum level. |
Levocetirizine | Daptomycin may decrease the excretion rate of Levocetirizine which could result in a higher serum level. |
Levofloxacin | Daptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level. |
Levoketoconazole | The serum concentration of Daptomycin can be increased when it is combined with Levoketoconazole. |
Levomilnacipran | Daptomycin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. |
Levosalbutamol | Daptomycin may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. |
Lidocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Lidocaine. |
Linagliptin | The serum concentration of Daptomycin can be increased when it is combined with Linagliptin. |
Liothyronine | Daptomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level. |
Lisinopril | Daptomycin may decrease the excretion rate of Lisinopril which could result in a higher serum level. |
Lithium carbonate | Daptomycin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
Lithium citrate | Lithium citrate may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Lixisenatide | Daptomycin may decrease the excretion rate of Lixisenatide which could result in a higher serum level. |
Lofexidine | Daptomycin may decrease the excretion rate of Lofexidine which could result in a higher serum level. |
Lomitapide | The serum concentration of Daptomycin can be increased when it is combined with Lomitapide. |
Lonafarnib | The serum concentration of Daptomycin can be increased when it is combined with Lonafarnib. |
Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Daptomycin. |
Loperamide | The serum concentration of Loperamide can be increased when it is combined with Daptomycin. |
Lopinavir | The serum concentration of Daptomycin can be increased when it is combined with Lopinavir. |
Loracarbef | Loracarbef may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Lorazepam | Daptomycin may decrease the excretion rate of Lorazepam which could result in a higher serum level. |
Lorcaserin | Daptomycin may decrease the excretion rate of Lorcaserin which could result in a higher serum level. |
Lornoxicam | Lornoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Lorpiprazole | Daptomycin may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. |
Lovastatin | The risk or severity of myopathy can be increased when Lovastatin is combined with Daptomycin. |
Loxapine | The serum concentration of Daptomycin can be increased when it is combined with Loxapine. |
Loxoprofen | Loxoprofen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Lubiprostone | Daptomycin may decrease the excretion rate of Lubiprostone which could result in a higher serum level. |
Lumacaftor | The serum concentration of Daptomycin can be decreased when it is combined with Lumacaftor. |
Lumiracoxib | Lumiracoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Lusutrombopag | The serum concentration of Lusutrombopag can be increased when it is combined with Daptomycin. |
Macitentan | Daptomycin may decrease the excretion rate of Macitentan which could result in a higher serum level. |
Magnesium carbonate | Daptomycin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. |
Magnesium chloride | Daptomycin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. |
Magnesium | Daptomycin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. |
Magnesium trisilicate | Daptomycin may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. |
Mangafodipir | Daptomycin may decrease the excretion rate of Mangafodipir which could result in a higher serum level. |
Mannitol | Mannitol may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Maprotiline | Daptomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level. |
Maribavir | The serum concentration of Daptomycin can be increased when it is combined with Maribavir. |
Mebeverine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mebeverine. |
Mecamylamine | Daptomycin may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
Meclofenamic acid | Meclofenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Medroxyprogesterone | Daptomycin may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level. |
Mefenamic acid | Mefenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Mefloquine | The serum concentration of Daptomycin can be increased when it is combined with Mefloquine. |
Megestrol acetate | Daptomycin may decrease the excretion rate of Megestrol acetate which could result in a higher serum level. |
Meloxicam | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Meloxicam. |
Memantine | Daptomycin may decrease the excretion rate of Memantine which could result in a higher serum level. |
Meperidine | Daptomycin may decrease the excretion rate of Meperidine which could result in a higher serum level. |
Mepivacaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Mepivacaine. |
Meropenem | Daptomycin may decrease the excretion rate of Meropenem which could result in a higher serum level. |
Mesalazine | Mesalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Metamfetamine | Daptomycin may decrease the excretion rate of Metamfetamine which could result in a higher serum level. |
Metamizole | Metamizole may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Metaxalone | Daptomycin may decrease the excretion rate of Metaxalone which could result in a higher serum level. |
Metformin | Daptomycin may decrease the excretion rate of Metformin which could result in a higher serum level. |
Methadone | Daptomycin may decrease the excretion rate of Methadone which could result in a higher serum level. |
Methazolamide | Methazolamide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Methimazole | Daptomycin may decrease the excretion rate of Methimazole which could result in a higher serum level. |
Methotrexate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Methotrexate. |
Methoxsalen | Daptomycin may decrease the excretion rate of Methoxsalen which could result in a higher serum level. |
Methyldopa | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Methyldopa. |
Methylene blue | The serum concentration of Daptomycin can be increased when it is combined with Methylene blue. |
Methylnaltrexone | Daptomycin may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. |
Methyltestosterone | Daptomycin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. |
Meticrane | Meticrane may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Metoclopramide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Metoclopramide. |
Metolazone | Metolazone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Metoprolol | Daptomycin may decrease the excretion rate of Metoprolol which could result in a higher serum level. |
Metyrapone | Daptomycin may decrease the excretion rate of Metyrapone which could result in a higher serum level. |
Midazolam | Daptomycin may decrease the excretion rate of Midazolam which could result in a higher serum level. |
Mifepristone | The serum concentration of Daptomycin can be increased when it is combined with Mifepristone. |
Migalastat | Daptomycin may decrease the excretion rate of Migalastat which could result in a higher serum level. |
Milnacipran | Daptomycin may decrease the excretion rate of Milnacipran which could result in a higher serum level. |
Milrinone | Daptomycin may decrease the excretion rate of Milrinone which could result in a higher serum level. |
Minocycline | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Minocycline. |
Mirabegron | The serum concentration of Daptomycin can be increased when it is combined with Mirabegron. |
Mitapivat | The serum concentration of Daptomycin can be increased when it is combined with Mitapivat. |
Montelukast | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Montelukast. |
Morphine | The serum concentration of Morphine can be increased when it is combined with Daptomycin. |
Moxisylyte | Daptomycin may decrease the excretion rate of Moxisylyte which could result in a higher serum level. |
Muzolimine | Muzolimine may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Mycophenolate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Mycophenolate mofetil. |
Mycophenolic acid | Daptomycin may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level. |
N-acetyltyrosine | Daptomycin may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. |
Nabumetone | Nabumetone may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Nadolol | Daptomycin may decrease the excretion rate of Nadolol which could result in a higher serum level. |
Nafarelin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nafarelin. |
Naldemedine | Daptomycin may decrease the excretion rate of Naldemedine which could result in a higher serum level. |
Nalmefene | Daptomycin may decrease the excretion rate of Nalmefene which could result in a higher serum level. |
Naloxone | Daptomycin may decrease the excretion rate of Naloxone which could result in a higher serum level. |
Naltrexone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Naltrexone. |
Naproxen | Naproxen may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Nateglinide | Daptomycin may decrease the excretion rate of Nateglinide which could result in a higher serum level. |
Nedaplatin | Daptomycin may decrease the excretion rate of Nedaplatin which could result in a higher serum level. |
Nedocromil | Daptomycin may decrease the excretion rate of Nedocromil which could result in a higher serum level. |
Nefazodone | Daptomycin may decrease the excretion rate of Nefazodone which could result in a higher serum level. |
Neomycin | Daptomycin may decrease the excretion rate of Neomycin which could result in a higher serum level. |
Neratinib | The serum concentration of Daptomycin can be increased when it is combined with Neratinib. |
Netilmicin | Daptomycin may decrease the excretion rate of Netilmicin which could result in a higher serum level. |
Netupitant | The serum concentration of Daptomycin can be increased when it is combined with Netupitant. |
Niacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Niacin. |
Nicorandil | Daptomycin may decrease the excretion rate of Nicorandil which could result in a higher serum level. |
Nifedipine | Daptomycin may decrease the excretion rate of Nifedipine which could result in a higher serum level. |
Nilotinib | The serum concentration of Daptomycin can be increased when it is combined with Nilotinib. |
Nilutamide | Daptomycin may decrease the excretion rate of Nilutamide which could result in a higher serum level. |
Nimesulide | Nimesulide may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Nintedanib | The serum concentration of Nintedanib can be increased when it is combined with Daptomycin. |
Nisoldipine | Daptomycin may decrease the excretion rate of Nisoldipine which could result in a higher serum level. |
Nitric Oxide | Daptomycin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level. |
Nitrofurantoin | Daptomycin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
Nitroprusside | Daptomycin may decrease the excretion rate of Nitroprusside which could result in a higher serum level. |
Nizatidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Nizatidine. |
Norfloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Norfloxacin. |
Norgestimate | The serum concentration of Daptomycin can be increased when it is combined with Norgestimate. |
Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Daptomycin. |
Octinoxate | Daptomycin may decrease the excretion rate of Octinoxate which could result in a higher serum level. |
Ofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ofloxacin. |
Olsalazine | Olsalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Daptomycin. |
Ombitasvir | The serum concentration of Ombitasvir can be increased when it is combined with Daptomycin. |
Opium | Daptomycin may decrease the excretion rate of Opium which could result in a higher serum level. |
Oseltamivir | Daptomycin may decrease the excretion rate of Oseltamivir which could result in a higher serum level. |
Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Daptomycin. |
Oxacillin | Daptomycin may decrease the excretion rate of Oxacillin which could result in a higher serum level. |
Oxaprozin | Oxaprozin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Oxazepam | Daptomycin may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
Oxetacaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Oxetacaine. |
Oxybenzone | Daptomycin may decrease the excretion rate of Oxybenzone which could result in a higher serum level. |
Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Oxybuprocaine. |
Oxyphenbutazone | Oxyphenbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Oxyquinoline | Daptomycin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. |
Paclitaxel | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Paclitaxel. |
Pacritinib | The serum concentration of Daptomycin can be increased when it is combined with Pacritinib. |
Palbociclib | The serum concentration of Daptomycin can be increased when it is combined with Palbociclib. |
Paliperidone | The serum concentration of Daptomycin can be increased when it is combined with Paliperidone. |
Palonosetron | Daptomycin may decrease the excretion rate of Palonosetron which could result in a higher serum level. |
Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Pamidronic acid. |
Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Daptomycin. |
Pantoprazole | Daptomycin may decrease the excretion rate of Pantoprazole which could result in a higher serum level. |
Parecoxib | Parecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Paritaprevir | The serum concentration of Paritaprevir can be increased when it is combined with Daptomycin. |
Paromomycin | Paromomycin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Patent Blue | Daptomycin may decrease the excretion rate of Patent Blue which could result in a higher serum level. |
Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Daptomycin. |
Pegaptanib | Daptomycin may decrease the excretion rate of Pegaptanib which could result in a higher serum level. |
Peginesatide | Daptomycin may decrease the excretion rate of Peginesatide which could result in a higher serum level. |
Pemetrexed | Daptomycin may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
Penbutolol | Daptomycin may decrease the excretion rate of Penbutolol which could result in a higher serum level. |
Penicillamine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Penicillamine. |
Pentaerythritol | Daptomycin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level. |
Pentamidine | Pentamidine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Pentastarch | Daptomycin may decrease the excretion rate of Pentastarch which could result in a higher serum level. |
Pentetic acid | Daptomycin may decrease the excretion rate of Pentetic acid which could result in a higher serum level. |
Pentobarbital | Daptomycin may decrease the excretion rate of Pentobarbital which could result in a higher serum level. |
Pentostatin | Daptomycin may decrease the excretion rate of Pentostatin which could result in a higher serum level. |
Pentoxifylline | Daptomycin may decrease the excretion rate of Pentoxifylline which could result in a higher serum level. |
Perindopril | Daptomycin may decrease the excretion rate of Perindopril which could result in a higher serum level. |
Permethrin | Daptomycin may decrease the excretion rate of Permethrin which could result in a higher serum level. |
Phenazopyridine | Phenazopyridine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Phenelzine | Daptomycin may decrease the excretion rate of Phenelzine which could result in a higher serum level. |
Phenindione | The risk or severity of bleeding can be increased when Daptomycin is combined with Phenindione. |
Phenol | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Phenol. |
Phenprocoumon | The risk or severity of bleeding can be increased when Daptomycin is combined with Phenprocoumon. |
Phentolamine | Daptomycin may decrease the excretion rate of Phentolamine which could result in a higher serum level. |
Phenylbutazone | Phenylbutazone may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Phenytoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Phenytoin. |
Pholcodine | Daptomycin may decrease the excretion rate of Pholcodine which could result in a higher serum level. |
Phosphoric acid | Daptomycin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. |
Phylloquinone | Daptomycin may decrease the excretion rate of Phylloquinone which could result in a higher serum level. |
Pibrentasvir | The serum concentration of Daptomycin can be increased when it is combined with Pibrentasvir. |
Picosulfuric acid | Daptomycin may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. |
Pindolol | Daptomycin may decrease the excretion rate of Pindolol which could result in a higher serum level. |
Piperacillin | Daptomycin may decrease the excretion rate of Piperacillin which could result in a higher serum level. |
Piracetam | Daptomycin may decrease the excretion rate of Piracetam which could result in a higher serum level. |
Piretanide | Piretanide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Piroxicam | Piroxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Pitavastatin | The risk or severity of myopathy can be increased when Pitavastatin is combined with Daptomycin. |
Pitolisant | The serum concentration of Daptomycin can be increased when it is combined with Pitolisant. |
Plazomicin | Daptomycin may decrease the excretion rate of Plazomicin which could result in a higher serum level. |
Plerixafor | Daptomycin may decrease the excretion rate of Plerixafor which could result in a higher serum level. |
Polythiazide | Polythiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Daptomycin. |
Ponatinib | The serum concentration of Daptomycin can be increased when it is combined with Ponatinib. |
Posaconazole | The serum concentration of Posaconazole can be increased when it is combined with Daptomycin. |
Potassium | Potassium may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Potassium acetate | Daptomycin may decrease the excretion rate of Potassium acetate which could result in a higher serum level. |
Potassium bicarbonate | Daptomycin may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. |
Potassium cation | Potassium cation may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Potassium chloride | Daptomycin may decrease the excretion rate of Potassium chloride which could result in a higher serum level. |
Potassium citrate | Potassium citrate may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Potassium nitrate | Daptomycin may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. |
Potassium perchlorate | Daptomycin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. |
Potassium sulfate | Daptomycin may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. |
Pralatrexate | Daptomycin may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
Pralidoxime | Daptomycin may decrease the excretion rate of Pralidoxime which could result in a higher serum level. |
Pralsetinib | The serum concentration of Daptomycin can be increased when it is combined with Pralsetinib. |
Pramipexole | Daptomycin may decrease the excretion rate of Pramipexole which could result in a higher serum level. |
Pramocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Pramocaine. |
Prasugrel | Daptomycin may decrease the excretion rate of Prasugrel which could result in a higher serum level. |
Pravastatin | The risk or severity of myopathy can be increased when Pravastatin is combined with Daptomycin. |
Prednisolone phosphate | The serum concentration of Prednisolone phosphate can be increased when it is combined with Daptomycin. |
Prednisone | Daptomycin may decrease the excretion rate of Prednisone which could result in a higher serum level. |
Pregabalin | Daptomycin may decrease the excretion rate of Pregabalin which could result in a higher serum level. |
Prilocaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Prilocaine. |
Probenecid | Daptomycin may decrease the excretion rate of Probenecid which could result in a higher serum level. |
Procainamide | Daptomycin may decrease the excretion rate of Procainamide which could result in a higher serum level. |
Procaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Procaine. |
Procaine benzylpenicillin | Daptomycin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. |
Procarbazine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Procarbazine. |
Promethazine | Daptomycin may decrease the excretion rate of Promethazine which could result in a higher serum level. |
Propafenone | The serum concentration of Daptomycin can be increased when it is combined with Propafenone. |
Propantheline | Daptomycin may decrease the excretion rate of Propantheline which could result in a higher serum level. |
Proparacaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Proparacaine. |
Propiverine | Daptomycin may decrease the excretion rate of Propiverine which could result in a higher serum level. |
Propofol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propofol. |
Propoxycaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Propoxycaine. |
Propranolol | Daptomycin may decrease the excretion rate of Propranolol which could result in a higher serum level. |
Propylthiouracil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Propylthiouracil. |
Prucalopride | Daptomycin may decrease the excretion rate of Prucalopride which could result in a higher serum level. |
Pyrantel | Daptomycin may decrease the excretion rate of Pyrantel which could result in a higher serum level. |
Pyrazinamide | Daptomycin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level. |
Pyridoxine | Daptomycin may decrease the excretion rate of Pyridoxine which could result in a higher serum level. |
Pyrithione | Daptomycin may decrease the excretion rate of Pyrithione which could result in a higher serum level. |
Quetiapine | Daptomycin may decrease the excretion rate of Quetiapine which could result in a higher serum level. |
Quinethazone | Quinethazone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Quinidine | Daptomycin may decrease the excretion rate of Quinidine which could result in a higher serum level. |
Quinine | The serum concentration of Daptomycin can be increased when it is combined with Quinine. |
Rabeprazole | Daptomycin may decrease the excretion rate of Rabeprazole which could result in a higher serum level. |
Raltegravir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Raltegravir. |
Ramelteon | Daptomycin may decrease the excretion rate of Ramelteon which could result in a higher serum level. |
Ranitidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ranitidine. |
Ranolazine | The serum concentration of Daptomycin can be increased when it is combined with Ranolazine. |
Rasagiline | Daptomycin may decrease the excretion rate of Rasagiline which could result in a higher serum level. |
Regorafenib | The serum concentration of Daptomycin can be increased when it is combined with Regorafenib. |
Relugolix | The serum concentration of Relugolix can be increased when it is combined with Daptomycin. |
Reserpine | The serum concentration of Daptomycin can be increased when it is combined with Reserpine. |
Resorcinol | Daptomycin may decrease the excretion rate of Resorcinol which could result in a higher serum level. |
Revefenacin | The serum concentration of Revefenacin can be increased when it is combined with Daptomycin. |
Ribavirin | Daptomycin may decrease the excretion rate of Ribavirin which could result in a higher serum level. |
Ribostamycin | Daptomycin may decrease the excretion rate of Ribostamycin which could result in a higher serum level. |
Rifamycin | The serum concentration of Daptomycin can be increased when it is combined with Rifamycin. |
Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Daptomycin. |
Riociguat | The serum concentration of Riociguat can be increased when it is combined with Daptomycin. |
Ripretinib | The serum concentration of Daptomycin can be increased when it is combined with Ripretinib. |
Risedronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Risedronic acid. |
Ritonavir | The serum concentration of Daptomycin can be increased when it is combined with Ritonavir. |
Rivaroxaban | The serum concentration of Rivaroxaban can be increased when it is combined with Daptomycin. |
Rizatriptan | Daptomycin may decrease the excretion rate of Rizatriptan which could result in a higher serum level. |
Rofecoxib | Rofecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Roflumilast | Daptomycin may decrease the excretion rate of Roflumilast which could result in a higher serum level. |
Rolapitant | The serum concentration of Daptomycin can be increased when it is combined with Rolapitant. |
Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Daptomycin. |
Ropivacaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Ropivacaine. |
Rosiglitazone | Daptomycin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level. |
Rosuvastatin | The risk or severity of myopathy can be increased when Rosuvastatin is combined with Daptomycin. |
Ruxolitinib | Daptomycin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. |
Sacubitril | Daptomycin may decrease the excretion rate of Sacubitril which could result in a higher serum level. |
Salbutamol | Daptomycin may decrease the excretion rate of Salbutamol which could result in a higher serum level. |
Salicylamide | Salicylamide may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Salicylic acid | Salicylic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Salmeterol | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Salmeterol. |
Salmon calcitonin | Salmon calcitonin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Salsalate | Salsalate may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Sapropterin | The serum concentration of Daptomycin can be increased when it is combined with Sapropterin. |
Saquinavir | The serum concentration of Daptomycin can be increased when it is combined with Saquinavir. |
Sarecycline | The serum concentration of Daptomycin can be increased when it is combined with Sarecycline. |
Saxagliptin | Daptomycin may decrease the excretion rate of Saxagliptin which could result in a higher serum level. |
Secobarbital | Daptomycin may decrease the excretion rate of Secobarbital which could result in a higher serum level. |
Selenious acid | Daptomycin may decrease the excretion rate of Selenious acid which could result in a higher serum level. |
Selenium | Daptomycin may decrease the excretion rate of Selenium which could result in a higher serum level. |
Selexipag | The serum concentration of Selexipag can be increased when it is combined with Daptomycin. |
Selumetinib | The serum concentration of Selumetinib can be increased when it is combined with Daptomycin. |
Sibutramine | Daptomycin may decrease the excretion rate of Sibutramine which could result in a higher serum level. |
Sildenafil | The serum concentration of Daptomycin can be increased when it is combined with Sildenafil. |
Silodosin | The serum concentration of Silodosin can be increased when it is combined with Daptomycin. |
Simeprevir | The serum concentration of Daptomycin can be increased when it is combined with Simeprevir. |
Simvastatin | The risk or severity of myopathy can be increased when Simvastatin is combined with Daptomycin. |
Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Daptomycin. |
Sitagliptin | The serum concentration of Sitagliptin can be increased when it is combined with Daptomycin. |
Sodium acetate | Daptomycin may decrease the excretion rate of Sodium acetate which could result in a higher serum level. |
Sodium aurothio | Daptomycin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. |
Sodium fluoride | Daptomycin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. |
Sodium sulfate | Daptomycin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. |
Sofosbuvir | The serum concentration of Sofosbuvir can be increased when it is combined with Daptomycin. |
Solriamfetol | Daptomycin may decrease the excretion rate of Solriamfetol which could result in a higher serum level. |
Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Daptomycin. |
Sorafenib | The serum concentration of Daptomycin can be increased when it is combined with Sorafenib. |
Sorbitol | Daptomycin may decrease the excretion rate of Sorbitol which could result in a higher serum level. |
Sotagliflozin | The serum concentration of Daptomycin can be increased when it is combined with Sotagliflozin. |
Sotorasib | The serum concentration of Daptomycin can be increased when it is combined with Sotorasib. |
Spironolactone | Spironolactone may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Stavudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Stavudine. |
Stiripentol | The excretion of Daptomycin can be decreased when combined with Stiripentol. |
Streptomycin | Daptomycin may decrease the excretion rate of Streptomycin which could result in a higher serum level. |
Strontium chloride | Daptomycin may decrease the excretion rate of Strontium chloride which could result in a higher serum level. |
Sucralfate | Daptomycin may decrease the excretion rate of Sucralfate which could result in a higher serum level. |
Sulbactam | Daptomycin may decrease the excretion rate of Sulbactam which could result in a higher serum level. |
Sulfadiazine | Daptomycin may decrease the excretion rate of Sulfadiazine which could result in a higher serum level. |
Sulfamethoxazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Sulfamethoxazole. |
Sulfasalazine | Sulfasalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Sulindac | Sulindac may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Sumatriptan | Daptomycin may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
Suvorexant | The serum concentration of Daptomycin can be increased when it is combined with Suvorexant. |
S Estrogens, A | Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level. |
S Estrogens, B | Daptomycin may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level. |
Tacrine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Tacrine. |
Tacrolimus | The serum concentration of Daptomycin can be increased when it is combined with Tacrolimus. |
Tadalafil | Daptomycin may decrease the excretion rate of Tadalafil which could result in a higher serum level. |
Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Daptomycin. |
Tamoxifen | The serum concentration of Daptomycin can be increased when it is combined with Tamoxifen. |
Tamsulosin | Daptomycin may decrease the excretion rate of Tamsulosin which could result in a higher serum level. |
Tasimelteon | Daptomycin may decrease the excretion rate of Tasimelteon which could result in a higher serum level. |
Tazemetostat | The serum concentration of Tazemetostat can be increased when it is combined with Daptomycin. |
Technetium | Daptomycin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. |
Technetium | Daptomycin may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. |
Technetium | Daptomycin may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. |
Technetium | Daptomycin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. |
Technetium | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Daptomycin. |
Teduglutide | Daptomycin may decrease the excretion rate of Teduglutide which could result in a higher serum level. |
Tegafur | Daptomycin may decrease the excretion rate of Tegafur which could result in a higher serum level. |
Tegaserod | The serum concentration of Tegaserod can be increased when it is combined with Daptomycin. |
Telaprevir | The serum concentration of Daptomycin can be increased when it is combined with Telaprevir. |
Telavancin | Daptomycin may decrease the excretion rate of Telavancin which could result in a higher serum level. |
Temazepam | Daptomycin may decrease the excretion rate of Temazepam which could result in a higher serum level. |
Temozolomide | Daptomycin may decrease the excretion rate of Temozolomide which could result in a higher serum level. |
Temsirolimus | The serum concentration of Daptomycin can be increased when it is combined with Temsirolimus. |
Tenofovir alafenamide | Tenofovir alafenamide may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Tenofovir disoproxil | The serum concentration of Tenofovir disoproxil can be increased when it is combined with Daptomycin. |
Tenoxicam | Tenoxicam may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Tepotinib | The serum concentration of Daptomycin can be increased when it is combined with Tepotinib. |
Terbinafine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Terbinafine. |
Terbutaline | Daptomycin may decrease the excretion rate of Terbutaline which could result in a higher serum level. |
Testolactone | Daptomycin may decrease the excretion rate of Testolactone which could result in a higher serum level. |
Testosterone | Daptomycin may decrease the excretion rate of Testosterone which could result in a higher serum level. |
Testosterone cypionate | Daptomycin may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
Testosterone enanthate | Daptomycin may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
Testosterone | Daptomycin may decrease the excretion rate of Testosterone propionate which could result in a higher serum level. |
Testosterone | Daptomycin may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. |
Tetracaine | The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Tetracaine. |
Tetracycline | Daptomycin may decrease the excretion rate of Tetracycline which could result in a higher serum level. |
Tetradecyl hydrogen | Daptomycin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. |
Tezacaftor | The serum concentration of Tezacaftor can be increased when it is combined with Daptomycin. |
Thiabendazole | Daptomycin may decrease the excretion rate of Thiabendazole which could result in a higher serum level. |
Thiethylperazine | Daptomycin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level. |
Tiaprofenic acid | Tiaprofenic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Ticagrelor | The serum concentration of Daptomycin can be increased when it is combined with Ticagrelor. |
Ticlopidine | Daptomycin may decrease the excretion rate of Ticlopidine which could result in a higher serum level. |
Tiludronic acid | Daptomycin may decrease the excretion rate of Tiludronic acid which could result in a higher serum level. |
Timolol | Daptomycin may decrease the excretion rate of Timolol which could result in a higher serum level. |
Tinidazole | Daptomycin may decrease the excretion rate of Tinidazole which could result in a higher serum level. |
Tiopronin | Daptomycin may decrease the excretion rate of Tiopronin which could result in a higher serum level. |
Tiotropium | Daptomycin may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
Tipranavir | The serum concentration of Daptomycin can be increased when it is combined with Tipranavir. |
Tirofiban | Daptomycin may decrease the excretion rate of Tirofiban which could result in a higher serum level. |
Tivozanib | The serum concentration of Tivozanib can be increased when it is combined with Daptomycin. |
Tixocortol | Daptomycin may decrease the excretion rate of Tixocortol which could result in a higher serum level. |
Tobramycin | The serum concentration of Tobramycin can be decreased when it is combined with Daptomycin. |
Tocopherol | Daptomycin may decrease the excretion rate of Tocopherol which could result in a higher serum level. |
Tolazamide | Daptomycin may decrease the excretion rate of Tolazamide which could result in a higher serum level. |
Tolbutamide | Daptomycin may decrease the excretion rate of Tolbutamide which could result in a higher serum level. |
Tolcapone | Daptomycin may decrease the excretion rate of Tolcapone which could result in a higher serum level. |
Tolfenamic acid | Tolfenamic acid may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Tolmetin | Tolmetin may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Tolterodine | Daptomycin may decrease the excretion rate of Tolterodine which could result in a higher serum level. |
Tolvaptan | Tolvaptan may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Topiramate | Daptomycin may decrease the excretion rate of Topiramate which could result in a higher serum level. |
Topotecan | The serum concentration of Topotecan can be increased when it is combined with Daptomycin. |
Torasemide | Torasemide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Toremifene | The serum concentration of Daptomycin can be increased when it is combined with Toremifene. |
Tositumomab | Daptomycin may decrease the excretion rate of Tositumomab which could result in a higher serum level. |
Trabectedin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trabectedin. |
Tramadol | Daptomycin may decrease the excretion rate of Tramadol which could result in a higher serum level. |
Trametinib | Daptomycin may decrease the excretion rate of Trametinib which could result in a higher serum level. |
Trastuzumab | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Daptomycin. |
Triamcinolone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triamcinolone. |
Triamterene | Triamterene may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Triazolam | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Triazolam. |
Trichlormethiazide | Trichlormethiazide may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy. |
Triethylenetetramine | Daptomycin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. |
Trifluridine | Daptomycin may decrease the excretion rate of Trifluridine which could result in a higher serum level. |
Trilaciclib | The serum concentration of Trilaciclib can be increased when it is combined with Daptomycin. |
Trimebutine | Daptomycin may decrease the excretion rate of Trimebutine which could result in a higher serum level. |
Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Trimethoprim. |
Trimetrexate | Daptomycin may decrease the excretion rate of Trimetrexate which could result in a higher serum level. |
Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Daptomycin. |
Tropisetron | Daptomycin may decrease the excretion rate of Tropisetron which could result in a higher serum level. |
Tucatinib | Tucatinib may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Daptomycin. |
Ubidecarenone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ubidecarenone. |
Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Daptomycin. |
Umbralisib | The serum concentration of Daptomycin can be increased when it is combined with Umbralisib. |
Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Daptomycin. |
Vaborbactam | Daptomycin may decrease the excretion rate of Vaborbactam which could result in a higher serum level. |
Valaciclovir | Valaciclovir may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Valbenazine | Daptomycin may decrease the excretion rate of Valbenazine which could result in a higher serum level. |
Valdecoxib | Valdecoxib may decrease the excretion rate of Daptomycin which could result in a higher serum level. |
Valganciclovir | Daptomycin may decrease the excretion rate of Valganciclovir which could result in a higher serum level. |
Vancomycin | Daptomycin may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
Vandetanib | The serum concentration of Daptomycin can be increased when it is combined with Vandetanib. |
Vardenafil | The serum concentration of Daptomycin can be increased when it is combined with Vardenafil. |
Varenicline | Daptomycin may decrease the excretion rate of Varenicline which could result in a higher serum level. |
Velpatasvir | The serum concentration of Daptomycin can be increased when it is combined with Velpatasvir. |
Vemurafenib | The serum concentration of Daptomycin can be increased when it is combined with Vemurafenib. |
Venetoclax | The serum concentration of Daptomycin can be increased when it is combined with Venetoclax. |
Venlafaxine | Daptomycin may decrease the excretion rate of Venlafaxine which could result in a higher serum level. |
Verapamil | The serum concentration of Daptomycin can be increased when it is combined with Verapamil. |
Vibrio cholerae | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Daptomycin. |
Vilanterol | Daptomycin may decrease the excretion rate of Vilanterol which could result in a higher serum level. |
Viloxazine | Daptomycin may decrease the excretion rate of Viloxazine which could result in a higher serum level. |
Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Daptomycin. |
Vincristine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Vincristine. |
Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Daptomycin. |
Voclosporin | The serum concentration of Daptomycin can be increased when it is combined with Voclosporin. |
Vorapaxar | The serum concentration of Daptomycin can be increased when it is combined with Vorapaxar. |
Vortioxetine | Daptomycin may decrease the excretion rate of Vortioxetine which could result in a higher serum level. |
Voxilaprevir | The serum concentration of Daptomycin can be increased when it is combined with Voxilaprevir. |
Warfarin | Daptomycin may decrease the excretion rate of Warfarin which could result in a higher serum level. |
Zaleplon | Daptomycin may decrease the excretion rate of Zaleplon which could result in a higher serum level. |
Zanamivir | Daptomycin may decrease the excretion rate of Zanamivir which could result in a higher serum level. |
Zidovudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Zidovudine. |
Zonisamide | The serum concentration of Daptomycin can be increased when it is combined with Zonisamide. |
Pregnancy and Lactation
AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.
Pregnancy
Based on findings from animal studies and its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman.
Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. Advise females of reproductive potential to use effective contraception during therapy and for at least 6 months after. Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use effective contraception during therapy and for 3 months after. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
Lactation
No information is available on the use of this drug during breastfeeding. Most experts consider breastfeeding contraindicated during maternal antineoplastic therapy. The effects in the nursing infant are unknown. The manufacturer recommends that breastfeeding be discontinued during therapy and for at least 14 days after.
How should this medicine be used?
Dactinomycin comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. The length of treatment depends on the type of cancer you have, the types of other drugs you are taking, and how well your body responds to treatment. Your doctor may need to stop or delay your treatment if you experience certain side effects. Dactinomycin may also be injected by a doctor directly into a specific the part of the body or the organ to treat the area where a tumor is located. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
Dactinomycin is also sometimes used to treat a type of cancer of the ovaries (a cancer that begins in the female reproductive organs where eggs are formed). Talk to your doctor about the risks of using this medication for your condition. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before receiving dactinomycin,
- tell your doctor and pharmacist if you are allergic to dactinomycin, any other medications, or any of the ingredients in dactinomycin injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
- tell your doctor if you have chickenpox or herpes zoster (shingles). Your doctor will probably not want you to receive dactinomycin injection.
- tell your doctor if you have previously received or are currently receiving radiation therapy.
- tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. You should not become pregnant or breast-feed while you are receiving dactinomycin. If you become pregnant while receiving dactinomycin, call your doctor. Dactinomycin may harm the fetus.
- do not have any vaccinations without talking to your doctor.
References